open access
Role of serum metalloproteinases 2 and 9 to assess the severity of COVID-19 in pregnant women: a prospective cross-sectional study
, 2, 3, 4, 4
Affiliations- 2nd Department of Obstetrics and Gynecology, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey
- Basaksehir Cam Sakura Hospital, Istanbul, Turkey
- Department of Clinical Biochemistry, Istinye University, Istanbul, Turkey
- Department of Obstetrics and Gynaecology, Istanbul Haseki Research and Education Hospital, Istanbul, Turkey
open access
Abstract
Objectives: To investigate the relationship between blood matrix metalloproteinases -2 and -9 levels and disease severity in pregnant women with COVID-19 infection.
Material and methods: A prospective cohort study was conducted at the Kanuni Sultan Suleyman Education and Research Hospital in Istanbul, Turkey. We measured serum MMPs-2 and-9 levels of the healthy pregnant controls and pregnant women with COVID-19 and sought to assess the status of these MMPs in pregnant women with COVID-19, especially in women with a severe form of COVID-19 as diagnosed by abnormal computed tomography (CT) findings in addition to severe clinical and laboratory findings.
Results: Of the healthy pregnant controls and pregnant women with COVID-19, the serum MMP-2 levels were comparable, but the MMP-9 level was lower in the pregnant women with COVID-19. Although the serum MMP2 level was somewhat lower in the women with COVID-19 with abnormal CT findings. The serum MMP-9 level of pregnant women with COVID-19 with abnormal CT was meaningfully lower.
Conclusions: In the pregnant women, COVID-19 decreases the serum MMP-9 but does not change the serum MMP-2. COVID-19 with abnormal CT findings causes minimal decrease in the serum MMP-2 but decreases the serum MMP-9 with abnormal CT findings. Considering the study variables of current study, the probability of LMWH-related MMP alterations needs to be a study topic to clarify the possible contribution of LMWH to the status of serum MMPs in pregnant women with COVİD-19 especially in the women with COVID-19 with abnormal CT findings.
Abstract
Objectives: To investigate the relationship between blood matrix metalloproteinases -2 and -9 levels and disease severity in pregnant women with COVID-19 infection.
Material and methods: A prospective cohort study was conducted at the Kanuni Sultan Suleyman Education and Research Hospital in Istanbul, Turkey. We measured serum MMPs-2 and-9 levels of the healthy pregnant controls and pregnant women with COVID-19 and sought to assess the status of these MMPs in pregnant women with COVID-19, especially in women with a severe form of COVID-19 as diagnosed by abnormal computed tomography (CT) findings in addition to severe clinical and laboratory findings.
Results: Of the healthy pregnant controls and pregnant women with COVID-19, the serum MMP-2 levels were comparable, but the MMP-9 level was lower in the pregnant women with COVID-19. Although the serum MMP2 level was somewhat lower in the women with COVID-19 with abnormal CT findings. The serum MMP-9 level of pregnant women with COVID-19 with abnormal CT was meaningfully lower.
Conclusions: In the pregnant women, COVID-19 decreases the serum MMP-9 but does not change the serum MMP-2. COVID-19 with abnormal CT findings causes minimal decrease in the serum MMP-2 but decreases the serum MMP-9 with abnormal CT findings. Considering the study variables of current study, the probability of LMWH-related MMP alterations needs to be a study topic to clarify the possible contribution of LMWH to the status of serum MMPs in pregnant women with COVİD-19 especially in the women with COVID-19 with abnormal CT findings.
Keywords
COVID-19; pregnancy; serum metalloproteinase-2; serum metalloproteinase-9; computed tomography; LMWH
About this articleTitle
Role of serum metalloproteinases 2 and 9 to assess the severity of COVID-19 in pregnant women: a prospective cross-sectional study
Journal
Issue
Article type
Research paper
Pages
638-644
Published online
2022-10-12
Page views
637
Article views/downloads
259
DOI
Bibliographic record
Ginekol Pol 2023;94(8):638-644.
Keywords
COVID-19
pregnancy
serum metalloproteinase-2
serum metalloproteinase-9
computed tomography
LMWH
Authors
Esra Can
Isil Turan Bakirci
Huri Bulut
Filiz Yarsilikal Guler
Ali Cetin
References (18)- Khan DS, Hamid LR, Ali A, et al. Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2021; 21(1): 801.
- Oshay RR, Chen MYC, Fields BKK, et al. COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients. Clin Imaging. 2021; 75: 75–82.
- Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: A national retrospective cohort study. PLoS Med. 2021; 18(11): e1003857.
- Celewicz A, Celewicz M, Michalczyk M, et al. Pregnancy as a Risk Factor of Severe COVID-19. J Clin Med. 2021; 10(22).
- Huber R, Attili/Abedalkhader R, Küper D, et al. Cellular and Molecular Effects of High-Molecular-Weight Heparin on Matrix Metalloproteinase 9 Expression. Int J Mol Sci. 2019; 20(7).
- Cancemi P, Aiello A, Accardi G, et al. The Role of Matrix Metalloproteinases (MMP-2 and MMP-9) in Ageing and Longevity: Focus on Sicilian Long-Living Individuals (LLIs). Mediators Inflamm. 2020; 2020: 8635158.
- Bassiouni W, Ali M, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. The FEBS Journal. 2021; 288(24): 7162–7182.
- Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci. 2020; 21(24).
- Cook R, Sarker H, Fernandez-Patron C. Pathologies of matrix metalloproteinase-2 underactivity: a perspective on a neglected condition . Can J Physiol Pharmacol. 2019; 97(6): 486–492.
- Henriet P, Emonard H. Matrix metalloproteinase-2: Not (just) a "hero" of the past. Biochimie. 2019; 166: 223–232.
- Lerum TV, Maltzahn NN, Aukrust P, et al. NOR-SOLIDARITY Consortium. Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Sci Rep. 2021; 11(1): 23205.
- Karimi MA, Radpour A, Sedaghat A, et al. Proposed Imaging Guidelines for Pregnant Women Suspected of Having COVID-19. Acad Radiol. 2020; 27(6): 902–903.
- Rahman S, Montero MT, Rowe K, et al. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021; 14(5): 601–621.
- Wei SQ, Bilodeau-Bertrand M, Liu S, et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021; 193(16): E540–E548.
- Lassi ZS, Ana A, Das JK, et al. A systematic review and meta-analysis of data on pregnant women with confirmed COVID-19: Clinical presentation, and pregnancy and perinatal outcomes based on COVID-19 severity. J Glob Health. 2021; 11: 05018.
- Mannello F, Jung K, Tonti GA, et al. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem. 2008; 41(18): 1466–1473.
- Grzela T, Brawura-Biskupski-Samaha R, Jelenska MM, et al. Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2008; 35(2): 159–161.
- D Avila-Mesquita C, Couto AES, Campos LCB, et al. MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients. Biomed Pharmacother. 2021; 142: 112067.
